EDITORIAL article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
This article is part of the Research TopicOrganoids for Drug DiscoveryView all 13 articles
Editorial: Innovative models of organoids for drug discovery
Provisionally accepted
- 1Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 2Hangzhou Cancer Hospital, Hangzhou, China
- 3Cancer Science Institute of Singapore, Singapore, Singapore
- 4National University of Singapore, Singapore, Singapore
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Organoids models represent valuable approaches for studying cancer development and drug resistance, and their in vitro culture allows extensive manipulations, such as genetic modification. Researchers have constructed organoids of specific lineages, including brain, liver, kidney, lung, intestinal, and skin, using human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs). Organoids derived from hESCs or iPSCs recapitulate numerous features, such as high structural complexity, size, and organization. However, most organoids lack the stromal, immune, neural, and vascular endothelial cell, limiting their utility in disease modeling. To model whole-body physiology and systemic diseases, multi-organ interaction chip with recirculating vascular flow and real-time monitoring system are required. Therefore, organoids models incorporating these key components represent an emerging platform with significant potential for evaluation of new drug efficacy and toxicity.On April 10, 2025, the FDA announced plan to phase out animal testing, replaced using (New Approach Methodologies, NAM), including (Artificial Intelligence, AI) computational models and organoids based efficacy and toxicity testing. Al, particularly deep Learning models, can now design completely novel molecular structures that have never been synthesized and predict the strength of drug-target interactions as well as potential toxicity. The integrating of AI, organoids, and computational biology has emerged as a transformative approach for exploring novel therapeutic strategies and providing human-relevant toxicity data. We, the editors from this research topic, thank all authors for their contributions. We also extend our sincere gratitude to the editors and reviewers for their dedicated efforts in reviewing, revising, and providing timely feedback on the manuscript.
Keywords: Organoids, iPSCs, drug screening, Drug response prediction, drug efficacy and toxicity
Received: 25 Oct 2025; Accepted: 12 Nov 2025.
Copyright: © 2025 Shen, You and Lingzhi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mingliang You, youml@zjhealth.org
Wang Lingzhi, csiwl@nus.edu.sg
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.